$TMDE

TMD Energy Limited Extends Memorandum of Agreement with Double Corporate Sdn Bhd by Two Years to Advance Green Bioenergy Collaboration

TMD Energy Limited (NYSE American: TMDE) said it has extended its Memorandum of Agreement with Double Corporate Sdn Bhd by two years to continue talks on sustainable bioenergy fuel collaboration for EU and Asia markets. The MOA, first signed June 18, 2025, was set to expire after one year; the extension keeps original terms and adds a two-year exclusivity period while both parties negotiate definitive agreements.

Original reporting
Published Jun 8, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TMD Energy Limited Extends Memorandum of Agreement with Double Corporate Sdn Bhd by Two Years to Advance Green Bioenergy Collaboration — source image
Decision brief

The 30-second read

$TMDEBullishLow
01

Why it matters

The extension provides additional time for evaluation and negotiation toward definitive collaboration agreements, with stated focus on waste-to-energy technologies and marine fuel market expansion.

02

Market read

A fresh strategic update for TMDE tied to sustainable marine biofuel collaboration, but without definitive commercial commitments.

03

What to watch

Traders may want to wait for definitive agreements, exclusivity scope details, and any quantified offtake/production timelines before re-rating the stock.

Relevance 5/10Novelty 5/10Timing: today’s PR; no definitive deal terms disclosed

Background

TMDE’s MOA with Double Corporate was initially signed June 18, 2025 for a one-year term; this extension adds two more years while keeping original terms.

Company-level read

Ticker impact

$TMDEBullishMedium confidence
Context

TMDE extended its MOA with Double Corporate for two years to explore sustainable bioenergy fuel collaboration for EU and Asia markets.

Expected impact

Modest positive bias; likely limited near-term impact unless followed by definitive agreements or commercial volumes.

Evidence & confidence

The article discloses an MOA extension (not a definitive contract or volume commitment), but it is a fresh, company-specific catalyst that can improve investor perception of strategic positioning in marine biofuels.

Market effects

Supports the narrative that marine bunkering players are pursuing waste-to-bioenergy pathways for EU/Asia compliance and demand growth.

Highlights EU and Asia as target markets, potentially increasing attention on regional biofuel supply partnerships.

Reinforces global SAF/SMF feedstock development (waste oils, palm derivatives) as a strategic theme for marine fuel transition.

Counterpoint

Because it’s only an MOA extension, it may reflect prolonged negotiations rather than imminent commercialization.

Key entities

  • TMD Energy Limited

    Malaysia/Singapore marine bunkering and related services provider; extended MOA for bioenergy collaboration.

  • Double Corporate Sdn Bhd

    Malaysian waste-to-bioenergy firm using ISCC-EU-approved technology to produce certified biofuels/feedstocks for SAF and SMF.

Related articles

$TMDEMedAI 8/10

TMD Energy Limited Announces Financial Results for the Six Months Ended December 31, 2025

TMD Energy Limited (TMDE) reported unaudited results for the six months ended Dec. 31, 2025 (First Half 2026). Total revenues fell 22.5% to about $247.6M; gross profit dropped 93.8% to about $0.7M (0.3% margin). Net loss was about $8.5M vs net income about $0.9M in 1H 2025. The company also extended a MOA with Double Corporate Sdn Bhd for two years to evaluate waste-based biofuels.

$BLCOLow

Bausch + Lomb Advances Oral Dry AMD Therapy BL1243 Following FDA Meeting

Bausch + Lomb (BLCO) reported progress in developing BL1243, an oral treatment for dry age-related macular degeneration (AMD), following a constructive FDA meeting. The FDA supported the proposed initial study design, which will assess the drug's safety and behavior in the body. If successful, BL1243 could offer a new treatment option for dry AMD patients. The company plans to initiate clinical trials in 2027.

$AMDMed

Samsung sets record Q3 earnings with Korea’s first-ever quarterly profit above 100 trillion won

Samsung Electronics reported record Q3 earnings, exceeding 100 trillion won. The company passed qualification tests for HBM4E chips with Nvidia and major hyperscalers. Samsung also agreed to supply HBM4 chips to AMD and plans to increase HBM4 DRAM output capacity by 70% to meet rising demand from Nvidia and AMD. According to the company, this expansion supports its focus on AI semiconductors.

$CAPRMedAI 8/10

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor presented two-year data on deramiocel, showing a 1.56-point difference in upper-limb decline for the delayed-start group. Patients treated for two years had a 3.4-point decline in PUL 2.0. Cardiac MRI data showed a 2.8% treatment effect on LVEF. The company plans to explore regulatory pathways outside the U.S. and monitor safety in combination therapies.